BioPharma Dive July 9, 2024
The Germany-based biotech startup is capitalizing on a surge of recent interest in therapies for autoimmune conditions.
SciRhom, a German biotechnology startup focused on autoimmune diseases, has raised a $70 million Series A funding round that will help the company bring its first drug prospect into human testing.
The fundraise announced Tuesday will support development of antibody drugs SciRhom aims to evaluate in inflammatory conditions. Its lead candidate, dubbed SRS-878, showed promise in preclinical studies in rheumatoid arthritis and inflammatory bowel disease and could begin its first human trial in Austria later this year.
As its name suggests, SciRhom is developing drugs aimed at a protein known as iRhom2 that’s involved in inflammation. iRhom2 helps regulate a key...
Today's Sponsors
Today's Sponsor